THE LATEST FROM MiRus
MoRe® News
Press Releases
Atlanta – August 1, 2025 – MiRus has received New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS) for the EUROPA® Posterior Cervical System, based on it’s proprietary rhenium alloys, for treatment of the cervical and upper thoracic spine. The EUROPA® PCF system is built around a 2.9 mm MoRe …
Read More MiRus Siegel™ TAVR US Early Feasibility Study (EFS) 30 Day Results Presented at NY Valves Meeting
ATLANTA – July 2, 2025 /PRNewswire/ – The MiRus Siegel™ Valve was featured in three podium presentations at the NY Valves meeting last week. Pradeep K. Yadav MD, Piedmont Heart Institute, Atlanta and Raj R. Makkar MD, Cedars Sinai Heart Institute, Los Angeles presented patient case studies and the 30 day results of US Early …
Read More MiRus Siegel™ TAVR: First EFS Cases
Atlanta – March 28, 2025 – MiRus is pleased to announce the launch of the US multi-center Early Feasibility Study of the Siegel™ 8-Fr aortic transcatheter heart valve (THV). The first two cases were successfully performed this week by Pradeep K. Yadav MD, Director of Structural Interventions, and Vinod H. Thourani MD, Marcus Chairman of …
Read More MiRus Receives Breakthrough Device Designation for Spine Implant
Atlanta – July 31, 2024 – MiRus has received Breakthrough Device Designation from the FDA for the EUROPA® Posterior Cervical System, based on it’s proprietary rhenium alloys, for treatment of the cervical and upper thoracic spine. The EUROPA® PCF system is built around a 2.9 mm MoRe rod which is much smaller than current commercial …
Read More MiRus Receives Breakthrough Device Designation for Spine Implant Read More »
MiRus Siegel™ TAVR: First in Human Results Presented at New York Valves
New York – June 6, 2024 – Pradeep K. Yadav MD, Director of Structural Interventions, Piedmont Heart Institute, Atlanta presented the initial experience with the MiRus Siegel™ 8-Fr aortic transcatheter heart valve (THV) at the New York Valves conference. Five sequential patients with severe, symptomatic aortic stenosis (AS) were treated at the Instituto Nacional Del …
Read More MiRus Siegel™ TAVR: First in Human Results Presented at New York Valves Read More »
MiRus® Announces FDA 510(k) Clearance for Molybdenum-Rhenium (MoRe®) Low Profile Anterior Cervical and Lateral Lumbar Plating Systems
ATLANTA — October 18, 2023 — MiRus® announced that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe® plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market. MoRe®, a proprietary molybdenum …
Read More MiRus® Announces Launch of Molybdenum-Rhenium Low Profile ATLAS™ MoRe® Foot and Ankle Plating System
ATLANTA — September 18, 2023— MiRus announces limited market release in the U.S. of its ATLAS™ MoRe® Foot and Ankle Plating System, the thinnest foot and ankle plate on the market for treatment of foot and ankle conditions. The molybdenum-rhenium alloy used in the plates allows for a dramatically smaller footprint of 1.0mm thickness without …
Read More MiRus® Announces Plans for Site of New Headquarters
MiRus announces plans for site of new headquarters with the purchase of the Franklin Gateway 6.72 acre property from the City of Marietta. The new headquarters will be a three-story facility comprising over 70,000 square feet. https://www.mariettaga.gov/CivicAlerts.aspx?AID=3474
Read More MiRus® Receives FDA 510(K) Clearance For<br>The Lowest Profile and Best-in-class Expandable Lumbar Interbody
ATLANTA- August 31, 2021 – MiRus LLC, the leading innovator in rhenium-based superalloy medical implants announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its IO™ Expandable Lumbar Interbody. The IO™ Expandable Lumbar Interbody can be utilized in both PLIF and TLIF procedures. It features the lowest insertion profile …
Read More MiRus® Raises $65 Million For Expansion of Rhenium-based Medical Devices
ATLANTA- July 27, 2021 – MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®). The round was led by Mammoth Scientific and multi-generational family offices who have supported …
Read More MiRus® Raises $65 Million For Expansion of Rhenium-based Medical Devices Read More »